Drug Profile
Research programme: transplant rejection therapy - ChemoCentryx
Alternative Names: TLRK-ALatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action CXCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (PO)
- 24 Jul 2007 Preclinical development is ongoing
- 17 May 2005 This programme is still in active development